The Neuroendocrine Tumor Research Foundation directs your individual donations to breakthrough scientific research. Since 2005, we have funded $34 million in research projects. The Neuroendocrine Research Foundation is a 501(c)(3) organization, so all donations are fully tax-deductible to the extent allowed by law. We are grateful to you for your generosity.
The Neuroendocrine Tumor Research Foundation directs your individual donations to breakthrough scientific research. Since 2005, we have funded $34 million in research projects. The Neuroendocrine Research Foundation is a 501(c)(3) organization, so all donations are fully tax-deductible to the extent allowed by law. We are grateful to you for your generosity.
The Neuroendocrine Tumor Research Foundation (NETRF) is the leading private funder of research into causes and treatments of neuroendocrine tumors (NETs) to improve and extend the lives of those living with NETs.
Additional US study sites are now participating in an ongoing clinical trial of peptide receptor radionuclide therapy (PRRT) with 177Lu-edotreotide as a first or second
Brittany Holzhauer had her whole future planned. A self-professed “dreamer” with incredible determination, she started her career as pharmacist in 2018 and with her husband Luke, welcomed her first child, Lorelei, in June of 2019.
“In 2012, my husband was diagnosed with a neuroendocrine tumor (NET) cancer. At that time, there was little information and few treatment options,” said Suzanne Ludlow, NETRF Board Member and generous benefactor of NETRF’s second edition of “Neuroendocrine Cancer: A Guide for Patients and Families.” Suzanne lost her beloved husband Vincent in 2017, but she’s honoring his life while supporting other patients and families navigating NETs as a new member of the NETRF Board of Trustees. Read more about Suzanne and Vincent’s story here.
A new clinical trial being conducted at a single center in Switzerland aims to explore a therapy using a novel somatostatin receptor subtype 2 antagonist labelled with Terbium-161 (161Tb-DOTA-LM3). The study is sponsored by University Hospital, Basel, in collaboration with the Swiss National Science Foundation and the Paul Sherrer Institute and builds upon research funded by NETRF.
A patient advocacy-led clinical research study aims to determine if patients who have rare tumors can benefit from matched molecular therapy based on the results of their genomic profiling. Patients with neuroendocrine tumors and unknown primaries may be eligible for this study. Sponsored by the TargetCancer Foundation, in collaboration with Foundation Medicine Inc., the TCF-001 TRACK (Target Rare Cancer Knowledge) Study uses next-generation sequencing to develop a comprehensive genomic profile of each participant’s tumor as well as their plasma circulating cell-free DNA (blood).
A new phase II clinical trial is exploring the effects of two approved chemotherapy drugs administered after surgery to treat adult patients who have high-risk, well-differentiated pancreatic neuroendocrine tumors (pNETS).
A new phase II clinical trial is evaluating the safety and effectiveness of 212Pb-DOTAMTATE in patients who have somatostatin receptor-expressing neuroendocrine tumors but who have not received peptide receptor radionuclide therapy, or PPRT.
By Josh Mailman Being a NET patient usually means some amount of travel for our care. While the pandemic has negatively impacted almost every aspect
This year’s NET Cancer Day focused on the all-too-common experience of delayed diagnosis and misdiagnosis among those with neuroendocrine tumors. INCA, International Neuroendocrine Cancer Alliance,
By the time she was 40 years old, Alicia Gutierrez had earned her stripes as a pink zebra with diagnoses of breast cancer and pancreatic neuroendocrine cancer.
